Advanced glycation endproducts: A biomarker for age as an outcome predictor after cardiac surgery?

Simm, Andreas; Wagner, Jürgen; Gursinsky, Torsten; Naß, Norbert; Friedrich, Ivar; Schinzel, Reinhard; Czeslik, E.; Silber, Rolf-Edgar; Scheubel, R.

doi:10.1016/j.exger.2007.03.006

Cited by 84 publications

(51 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A direct linear correlation between CML levels in the pericardial fluid and the age of the patients was shown where mean CML level of 260.8 ± 19.7 ng/mL was detected in patients with mean age 52.2 ± 1.3 years, mean CML level of 293.4 ± 18.8 ng/ mL was identified in patients with mean age 65.8 ± 0.6 years and mean CML level of 357.0 ± 28.3 ng/mL was recorded at mean age 75.1 ± 0.6 years [30] . In addition, AGEs accumulate at a much higher rate in diabetics than in normal population.…”

Section: Ages and Cardiovascular Diseasementioning

confidence: 98%

Role of advanced glycation end products in cardiovascular disease

Hegab

Gibbons²,

Neyses

et al. 2012

WJC

280

193

View full text Add to dashboard Cite

Advanced glycation end products (AGEs) are produced through the non enzymatic glycation and oxidation of proteins, lipids and nucleic acids. Enhanced formation of AGEs occurs particularly in conditions associated with hyperglycaemia such as diabetes mellitus (DM). AGEs are believed to have a key role in the development and progression of cardiovascular disease in patients with DM through the modification of the structure, function and mechanical properties of tissues through crosslinking intracellular as well as extracellular matrix proteins and through modulating cellular processes through binding to cell surface receptors [receptor for AGEs (RAGE)]. A number of studies have shown a correlation between serum AGE levels and the development and severity of heart failure (HF). Moreover, some studies have suggested that therapies targeted against AGEs may have therapeutic potential in patients with HF. The purpose of this review is to discuss the role of AGEs in cardiovascular disease and in particular in heart failure, focussing on both cellular mechanisms of action as well as highlighting how targeting AGEs may represent a novel therapeutic strategy in the treatment of HF.

show abstract

Section: Ages and Cardiovascular Diseasementioning

confidence: 98%

Role of advanced glycation end products in cardiovascular disease

Hegab

Gibbons²,

Neyses

et al. 2012

WJC

280

193

View full text Add to dashboard Cite

show abstract

“…Age dependent AGE accumulation has for example been shown on human cartilage, skin collagen and pericardial fluid (Dyer et al 1992;Verzijl et al 2000;Simm et al 2007). AGE content in the hippocampus allows the estimation of the age of human cadavers (Sato et al 2001) and skin collagen glycation and glycoxidation rates are associated with early deaths in C57BL/6NNia mice (Sell et al 2000).…”

Section: Introductionmentioning

confidence: 99%

Preconditioning with Maillard reaction products improves antioxidant defence leading to increased stress tolerance in cardiac cells

Ruhs

Naß

Bartling

et al. 2010

Experimental Gerontology

View full text Add to dashboard Cite

International audienceAdvanced glycation end products (AGEs) are considered as biomarkers of ageing and are associated with several degenerative diseases. Besides endogenous formation, significant amounts of AGEs are taken up with food. Although nutritional AGEs are considered as undesirable, proinflammatory agents, they may also enclose potentially beneficial antioxidants. We used rodent cardiac cells to evaluate if food AGEs, present in bread crust, can modify the cellular antioxidant defence. Mice were fed with bread crust containing diet to prove the in-vivo relevance for the heart. In mouse cardiac fibroblasts, bread crust extract induced a moderate elevation of ROS production causing an activation of p42/p44, p38 and NF-κB, followed by increased expression of antioxidative enzymes. Preconditioning studies demonstrated that this was sufficient to protect cardiac fibroblasts and rat adult cardiac myocytes against severe oxidative stress. Furthermore, mice, fed a bread crust containing diet, exhibited a similarly improved cardiac expression of antioxidative defence genes. The consumption of AGEs can therefore contribute to an improved antioxidant status of the heart, thus exhibiting cardioprotective effects in case of severe oxidative stress as in ischemia reperfusion injury. Also, these data show that the exclusive interpretation of circulating AGEs as pathophysiological biomarkers of ageing might be misleading

show abstract

“…In fact, AGEs activated RAGE expression, inhibited PPARγ expression, enhanced intracellular ROS formation and increased neutrophil-endothelial adhesion. AGE levels were proved to be associated with poor outcome and adverse events in patients after cardiac surgery; AGEs were also related with prolonged intubations and long hospitalization in Intensive Care Unit (46). Increased serum levels of AGEs, as well as skin tissue values (47), can predict total and cardiovascular mortality in patients with diabetes during a long term follow-up (4).…”

Section: Ages In Cardiovascular Diseasementioning

confidence: 99%

Pharmacologic approaches against Advanced Glycation End Products (AGEs) in diabetic cardiovascular disease

et al. 2015

View full text Add to dashboard Cite

Context: Advanced Glycation End-Products (AGEs) are signaling proteins associated to several vascular and neurological complications in diabetic and non-diabetic patients. AGEs proved to be a marker of negative outcome in both diabetes management and surgical procedures in these patients. The reported role of AGEs prompted the development of pharmacological inhibitors of their effects, giving rise to a number of both preclinical and clinical studies. Clinical trials with anti-AGEs drugs have been gradually developed and this review aimed to summarize most relevant reports. Evidence Acquisition: Evidence acquisition process was performed using PubMed and ClinicalTrials.gov with manually checked articles. Results: Pharmacological approaches in humans include aminoguanidine, pyridoxamine, benfotiamine, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, statin, ALT-711 (alagebrium) and thiazolidinediones. The most recent promising antiAGEs agents are statins, alagebrium and thiazolidinediones. The role of AGEs in disease and new compounds interfering with their effects are currently under investigation in preclinical settings and these newer anti-AGEs drugs would undergo clinical evaluation in the next years. Compounds with anti-AGEs activity but still not available for clinical scenarios are ALT-946, OPB-9195, tenilsetam, LR-90, TM2002, sRAGE and PEDF. Conclusions: Despite most studies confirm the efficacy of these pharmacological approaches, other reports produced conflicting evidences; in almost any case, these drugs were well tolerated. At present, AGEs measurement has still not taken a precise role in clinical practice, but its relevance as a marker of disease has been widely shown; therefore, it is important for clinicians to understand the value of new cardiovascular risk factors. Findings from the current and future clinical trials may help in determining the role of AGEs and the benefits of anti-AGEs treatment in cardiovascular disease.

show abstract

Advanced glycation endproducts: A biomarker for age as an outcome predictor after cardiac surgery?

Cited by 84 publications

References 44 publications

Role of advanced glycation end products in cardiovascular disease

Role of advanced glycation end products in cardiovascular disease

Preconditioning with Maillard reaction products improves antioxidant defence leading to increased stress tolerance in cardiac cells

Pharmacologic approaches against Advanced Glycation End Products (AGEs) in diabetic cardiovascular disease

Contact Info

Product

Resources

About